![](\"https:\/\/mms.businesswire.com\/media\/20260610640152\/en\/2828477\/4\/Laverock_logo.jpg\"){kind=logo}
<\/a><\/a>\nLaverock\u2019s platform technology enables programmable, tunable and multiplex gene control for both endogenous targets and for transgenically expressed payloads. In its T-cell programme (LVK201), the platform is designed to improve CAR-T cell anti-tumour activity without compromising safety. The latest data from ovarian cancer models, presented<\/a> at the American Society of Cell and Gene Therapy (ASCGT) Annual Meeting in May, demonstrate that the Company\u2019s technology can improve solid tumour control by targeting three distinct immunomodulatory pathways simultaneously. Previous studies have also shown that, because the technology harnesses T-cell activation dynamics to act only when needed, safety can be significantly improved compared with alternative approaches.<\/p> \nThese findings inform development of Laverock\u2019s lead programme whilst also providing broader validation of the platform, establishing a foundation for future tailored therapies across a range of solid tumour types. To realise this Laverock will apply AI and single-cell analytical approaches backed by recently announced<\/a> grant funding.<\/p> \nIn its macrophage programme (LVK301), Laverock\u2019s platform technology is used to control macrophage cell phenotype and regulate the delivery of an immunomodulatory payload. The Company has shown that these engineered cells can both control tumour growth, and convert the \u2018cold\u2019, immunosuppressive solid tumour microenvironment to a \u2018hot\u2019 state, enabling the body\u2019s immune system to attack the tumour. These findings provide strong validation of Laverock\u2019s macrophage programme for oncology and open the way to applying myeloid biology to address additional disease classes.<\/p> \nLaverock is now engaged with a range of partner organisations, defining non-clinical and clinical strategy, to provide a de-risked route to early clinical validation.<\/p> \nDavid Venables, Laverock Therapeutics CEO, said: \u201cThese key data points from our oncology programmes highlight the capabilities and strength of our platform technology, and provide a clear route to lead programme selection and progression into non-clinical studies. Solid tumours remain an area of huge unmet need for cancer patients, and we look forward to moving our differentiated therapies towards the clinic.\u201d<\/p> \nFor more information, please visit www.laverocktx.com<\/a><\/p>